Early decisions in CHO host selection, cell line development, and process strategy can shape a biologics program long before it reaches the clinic. Choices made upstream can affect titer, stability, development timelines, tech transfer, downstream readiness, and the path from research to GMP manufacturing.
In this webinar, Demeetra and NorthX Biologics discuss what biologics teams should know before CHO selection affects the CMC path. The conversation features Magnus Gustafsson, CCO of NorthX Biologics, and Jack Crawford, CEO of Demeetra, focusing on practical decisions to protect program timelines, margins, and asset value.
What the Webinar Covers
- The role of CHO host biology in cell line performance
- Why integration strategy matters for timelines, titer, and instability risk
- How CLD-to-GMP continuity can help compress timelines from cell line delivery to IND readiness
- Recent high-titer mAb data generated using Demeetra’s CLD platform, including CleanCut GS CHO cells and Harbor-IN transposase
- Live Q&A with Demeetra and NorthX Biologics
Why It Matters
For biologics teams, the transition from cell line development to GMP manufacturing is not just a handoff. It can introduce technical, operational, licensing, and timeline risks if early platform decisions are not aligned with later-stage requirements.
Demeetra and NorthX Biologics offer an integrated path from cell line development through coordinated GMP manufacturing, designed to help teams move from gene to clinical material with fewer resets, reduced transfer friction, and greater continuity across development stages.